secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2025-12-05T23:59:59+00:00
Accession:  0001193125-25-309621
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma amends bylaws to modernize shareholder proposals and align with DGCL
--------------------------------------------------------------------------------

- Removed requirement for nominated directors to provide support information except on independence.
- Limited disclosure of supporting stockholders to those financially backing the proposal.
- Added disclosure requirements for certain extrinsic arrangements in director nomination notices.
- Clarified that updates to proposals (e.g., new nominees) constitute new proposals subject to same procedures.
- Conformed notice provisions and stockholder list requirements to DGCL Sections 232 and 219.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525309621/0001193125-25-309621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312525309621/d13123d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-309621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer